Atlas Genetics Appoints Bob Johnston As Chief Financial Officer
Expansion of US Office
Bath, UK, January 8, 2016. Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces the appointment of Bob Johnston as Chief Financial Officer, who will be based in the recently opened Boston office.
Bob has over 20 years of experience in the life science industry where he has a very successful track record in all aspects of growing companies. His experience includes substantial equity and debt fund raisings, mergers/sales and acquisitions and taking companies public in the US. His extensive CFO expertise includes the successful growth and acquisition of Ascension Orthopedics, Tutogen Medical and Oncormed and the successful acquisition of Scientific Protein Laboratories. Bob will be located at the Boston office along with Keith Stauffer, VP Sales and Marketing, whose appointment was announced in November.
John Clarkson, CEO of Atlas Genetics, said: “We are delighted to welcome Bob to Atlas Genetics. With the CE mark for our first product expected shortly, Bob’s broad experience in the life sciences industry will be invaluable to Atlas Genetics as we enter our next phase of growth.”
Bob Johnston, CFO of Atlas Genetics, added: “With the anticipated launch of the Company's first product, 2016 will be an important year and I look forward to working with John and his team in growing Atlas Genetics into a major force in point of care molecular diagnostics. I believe the Company has great potential in this field.”
Contact details:
Atlas Genetics Ltd:
Tel: +44 (0) 1225 717930?
John Clarkson
FTI Consulting:
Tel: +44 (0) 20 3727 1000
Mo Noonan / Matthew Moss
NOTES TO EDITORS
Atlas Genetics Ltd (www.atlasgenetics.com)
Atlas Genetics develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases. The Atlas Genetics io® System uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability. The Company has its head office and R&D facilities near Bath in the UK, with a commercial office in Boston, USA.
Bath, UK, January 8, 2016. Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces the appointment of Bob Johnston as Chief Financial Officer, who will be based in the recently opened Boston office.
Bob has over 20 years of experience in the life science industry where he has a very successful track record in all aspects of growing companies. His experience includes substantial equity and debt fund raisings, mergers/sales and acquisitions and taking companies public in the US. His extensive CFO expertise includes the successful growth and acquisition of Ascension Orthopedics, Tutogen Medical and Oncormed and the successful acquisition of Scientific Protein Laboratories. Bob will be located at the Boston office along with Keith Stauffer, VP Sales and Marketing, whose appointment was announced in November.
John Clarkson, CEO of Atlas Genetics, said: “We are delighted to welcome Bob to Atlas Genetics. With the CE mark for our first product expected shortly, Bob’s broad experience in the life sciences industry will be invaluable to Atlas Genetics as we enter our next phase of growth.”
Bob Johnston, CFO of Atlas Genetics, added: “With the anticipated launch of the Company's first product, 2016 will be an important year and I look forward to working with John and his team in growing Atlas Genetics into a major force in point of care molecular diagnostics. I believe the Company has great potential in this field.”
Contact details:
Atlas Genetics Ltd:
Tel: +44 (0) 1225 717930?
John Clarkson
FTI Consulting:
Tel: +44 (0) 20 3727 1000
Mo Noonan / Matthew Moss
NOTES TO EDITORS
Atlas Genetics Ltd (www.atlasgenetics.com)
Atlas Genetics develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases. The Atlas Genetics io® System uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability. The Company has its head office and R&D facilities near Bath in the UK, with a commercial office in Boston, USA.